ACR Journals on Air Podcast


Welcome to ACR Journals on Air, the ACR’s newest podcast series featuring interviews, commentary, and analysis on research from our three peer-reviewed journals: Arthritis & Rheumatology, Arthritis Care & Research, and ACR Open Rheumatology. Join us each episode for engaging discussions with authors and independent experts about recently published studies, their implications for clinical care, and how they move the field of rheumatology forward.

Whether it’s an expert analysis of a manuscript or deep dive with an author—our goal is the same—to understand the impact of the science and bring it from the bench to the bedside.

Podcast Host

Victoria Shanmugam

Victoria Shanmugam, MBBS, MRCP, CCD, has clinical expertise caring for patients with autoimmune diseases, vasculitis, and chronic wounds. She has led several research studies investigating scleroderma, hidradenitis suppurativa, and the interplay of the host immune response and the microbiome in chronic wounds. Dr. Shanmugam is a frequently invited speaker at professional meetings. Her work in wound healing, hidradenitis, and scleroderma has been published in high-impact peer-reviewed journals, such as Arthritis Care and Research, Current Opinion in Rheumatology, International Wound Journal, and Clinical Rheumatology. Connect with Dr. Shanmugam on Twitter (@VickiShanmugam).


New episodes will be available twice a month on Tuesdays.

Episode 32 – A Noble Goal

Episode 31 – Congenital Heart Block

Episode 30 – MRI Definition of OA

Episode 29 – How Do You Feel About Your Fingers?

Episode 28 – Imaging Vasculitis with PET

Browse previous episodes in the ACR Journals on Air archive.

Episode Show Notes

End-stage renal disease is a dangerous reality for those who suffer from lupus nephritis (LN), despite improvements in immunosuppressive therapy in the last 20 years. We are joined by Brad H. Rovin, MD, FACP, FASN, first author of the manuscript, Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial, recently published in Arthritis & Rheumatology. This study was a post hoc analysis of the NOBILITY trial and was conducted to assess kidney-related outcomes in patients using Obinutuzumab.


Brad H. Rovin, MD, FACP, FASN

Brad H. Rovin, MD, FACP, FASN - Brad H. Rovin, MD, FACP, FASN, is the Lee A. Hebert Professor of Nephrology. Dr. Rovin received his Bachelor of Science in Chemical Engineering from Northwestern University in Evanston, IL and his Doctor of Medicine from the University of Illinois Medical School in Chicago. He completed a residency in Internal Medicine at Barnes Hospital in St. Louis, and a Fellowship in Nephrology at Washington University School of Medicine, St. Louis. He joined the College of Medicine Faculty in 1990, became Director of the Division of Nephrology in 2004, and served as Vice Chairman of Medicine for Research from 2009-2019. In 2019, he became the Medical Director of the Ohio State University Clinical Research Management Institute.

Dr. Rovin has had several leadership roles in the American Society of Nephrology, including running the Glomerular Diseases Pre-Course and Co-Editing NephSAP-Glomerular Diseases, a continuing education program of the ASN. Most recently he was appointed Deputy Editor of Kidney International, the flagship journal of the International Society of Nephrology. He also is co-chair for glomerular disease guideline development for the Kidney Disease Improving Global Outcomes effort.

Dr. Rovin studies the immunopathogenesis of glomerular and autoimmune diseases. He is heavily involved in clinical trial development and design for investigator-initiated and industry-sponsored trials. He is a founding member of NephroNet, a grass-roots nephrology community clinical trial organization, and the Lupus Nephritis Clinical Trials Network. He is and has been the Principal Investigator on several trials of novel therapeutics for glomerular diseases.

Related Links:

Don’t forget to like, share, and subscribe!

Submit Show Feedback

In this episode of ACR Journals on Air, we turn our attention to a rare but challenging and heart-breaking complication of rheumatic disease, congenital heart block. Sir Deryck and Lady Va Maughan Professor of Rheumatology and Director of the Division of Rheumatology at New York University School of Medicine, Jill P. Buyon, MD, joins us today to present her latest research, Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block.


Jill P. Buyon, MD

Jill P. Buyon, MD - Sir Deryck and Lady Va Maughan Professor of Rheumatology and Director of the Division of Rheumatology at New York University School of Medicine; Director of the NYU Lupus Center, Jill P. Buyon, MD, is internationally recognized as a physician scientist specializing in translational research and management of systemic lupus erythematosus, lupus nephritis, neonatal lupus, and rheumatic diseases in pregnancy. Dr. Buyon received her medical degree from the Albert Einstein College of Medicine, New York, NY and continued there for residency in internal medicine.

Dr. Buyon founded the HJD Lupus Clinic and has served as its director to this day. She led the first multicenter study in SLE, supported by NIAMS, which resulted in a paradigm change regarding the safety of contraceptive estrogens and hormone replacement.

Dr. Buyon has been an active member of the Accelerating Medicines Partnership as she continues to lead the effort in deconstructing and reconstructing lupus nephritis.

She has served on numerous NIH Grant Review Committees including six years on the Arthritis and Musculoskeletal Diseases K and T32 Award grant peer review committee and four years on the NIH Peer Review Advisory Committee (PRAC).

In 2018, she was appointed as a member of the NIAMS Advisory Council.

Related Links:

Don’t forget to like, share, and subscribe!

Submit Show Feedback

In this episode of ACR Journals on Air, we are joined by lead author and social media influencer Jean Liew, MD, MS, to dive into two studies that endeavored to define knee osteoarthritis (OA) through magnetic resonance imaging (MRI) imagery. We discuss the following manuscripts:


Jean Liew, MD, MS

Jean Liew, MD, MS - Jean Liew, MD, MS, earned her MD at the University of Texas Medical Branch in Galveston, TX, and completed her internal medicine residency at Oregon Health & Science University in Portland, OR, followed by rheumatology fellowship at the University of Washington in Seattle, WA. She concurrently earned an MS in epidemiology through the University of Washington School of Public Health. She is currently Assistant Professor of Medicine at Boston University School of Medicine and conducts clinical research in osteoarthritis, axial spondyloarthritis, and the intersection of COVID-19 with rheumatic disease. You can follow Dr. Liew on X (formerly Twitter) at her handle, @rheum_cat.

Don’t forget to like, share, and subscribe!

Submit Show Feedback

In this episode, we are joined by John D. Pauling, BMedSci, BMBS, FRCP, PhD. Dr. Pauling is the senior author of the manuscript Assessment of the Systemic Sclerosis-Associated Raynaud’s Phenomenon Questionnaire: Item Bank and Short Form Development, which endeavored to “develop, refine and score a novel patient-reported outcome instrument to assess the severity and impact of Raynaud’s phenomenon (RP) in systemic sclerosis (SSc)”. We discuss the challenges associated with measuring one of the most common disease manifestations of scleroderma, Raynaud’s, and how the Assessment of Systemic Sclerosis-Associated Raynaud’s Phenomenon (ASRAP) questionnaire was harmonious in the paper’s results and final conclusions.


John D. Pauling, BMedSci, BMBS, FRCP, PhD

John D. Pauling, BMedSci, BMBS, FRCP, PhD - John D. Pauling, BMedSci, BMBS, FRCP, PhD, is a consultant rheumatologist at North Bristol NHS Trust and Honorary Senior Lecturer in the School of Translational Sciences at the University of Bristol. Dr. Pauling was awarded the Arthritis Research Campaign Medal before qualifying from Nottingham University Medical School in 2002. In 2009 he was awarded the Dando fellowship, jointly funded by the Raynaud’s & Scleroderma Association and Royal College of Physicians. His PhD research helped Dr. Pauling to develop an interest in outcome measures in systemic sclerosis (SSc) research, particularly in relation to peripheral microvascular dysfunction in scleroderma. He has developed and validated new methods for assessing digital vasculopathy including patient reported outcome instruments and laser-derived methods in Raynaud’s phenomenon (RP) and systemic sclerosis. Dr. Pauling is a member of the EULAR Microcirculation study group and has contributed to recent initiatives of the UK Scleroderma Study Group. He has published over 130 peer-reviewed journal articles and several book chapters in the field of peripheral vascular disease and systemic sclerosis (h-index 30). He has presented at multiple international meetings.

Related Links:

Don’t forget to like, share, and subscribe!

Submit Show Feedback

Assessing disease activity in large vessel vasculitis can be a challenge. As imaging techniques evolve, clinicians must evaluate how to harness new imaging modalities in clinical care. In an attempt to predict the progression of large vessel vasculitis (LVV), our guest, Kaitlin Quinn, MD, used the vascular activity seen on a fluorodeoxyglucose-positron emission tomography (FDG-PET) scan to determine if there is an observable association with angiographic change. Author of the study Association of 18F-Fluorodeoxyglucose–Positron Emission Tomography Activity With Angiographic Progression of Disease in Large Vessel Vasculitis, Dr. Quinn breaks down her study and its methods along with her observations and findings.


Kaitlin Quinn, MD

Kaitlin Quinn, MD - Kaitlin Quinn, MD, received her medical degree from New York Medical College. She completed her internal medicine residency training and rheumatology fellowship training at Georgetown University Hospital. She subsequently completed a two-year Vasculitis Clinical Research Consortium - Vasculitis Foundation Fellowship within the NIAMS Vasculitis Translational Research Program where she focused on vasculitis from a clinical and research perspective. Dr. Quinn is board certified in internal medicine and rheumatology.

Related Links:

Don’t forget to like, share, and subscribe!

Submit Show Feedback

Subscribe & Rate

Subscribe to our podcasts in your favorite podcast listening platform, and they’ll notify you when new episodes are available. Like what you hear? Don’t forget to leave a review!


Podcast Feedback

We love to hear from our listeners. Tell us how we are doing.

We use cookies on our website to improve our service to you and for security purposes. By continuing to use our site without changing your browser cookie settings, you agree to our cookie policy and the use of cookies. See ACR Policies